Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
MarketViking,
Totally agree. The running commentary geeing on rises and falls and sweating over each intraday movement isn’t doing anyone any good.
It would seem that despite the positive steps the company are making and have demonstrated in December/January, many require a weekly (or in fact daily) RNS to prove an investment case. Each to their own and good luck to all genuine holders.
I see Sangi is on the charm offensive again… (with emphasis on offensive 😂)
Couple of dates for the diary re AGL
- Boston DDR Inhibitor Summit 30th January
- AJ Bell & Shares Magazine Investor Event 6th February
Hi BOJO
Here’s the slide presentation from last weeks Proactive Event. Slide 9 shows clearly the authorised sales and commercialisation locations worldwide. (Inc USA).
https://angleplc.com/wp-content/uploads/2024/01/ANGLE-Presentation-Proactive-Investors-11jan24.pdf
By the way Bantham if you can find an element of my last message, that you’ve criticised, that doesn’t directly reference an official RNS, article or presentation then I look forward to hearing it. I’d you’re going to accused me of ramping then please do back it up.
Bantham, if you check my recent and past posts you’ll see if have only referenced RNS’s, articles and links official sourced and relevant to AGL today. You sadly, however, have encouraged me, and others, to ditch our AGL stock due to your prejudices and poor investment decisions in the past. You’ve lost many due to those decisions and I sympathise.
On that note I look forward to AGL shares flourishing in 2024. Good luck with your other investments Bantham.
No worries NikNak. This board is an interesting me!
Let’s hope AGL see’s us right in our investments moving forward 👍🏻
Hi NikNak,
I’ve never said the presentation was a disaster. Quite the opposite. If you look back through my messages, my friend was there and relayed all of the details to me. I have emailed proactive to gee them up into getting the recording uploaded asap. All sounds good to me re AGL
Here’s a brief upside overview for new and prospective investors:
Here’s a thread as to why I’ve invested in #AGL:
Parsortix CTC Timor cell harvesting device has:
- US FDA Approval
- EU CE Mark
- UK UKCA Mark
- 26 granted patents inc USA, China, Europe, Japan, Canada & Australia until 2034
- Rights to market in USA, UK & Europe currently
Financials:
- Debt Free
- Cash in the bank of £15m = over 50% of current MCAP
- Fully funded cash runway until Q2 2025
- 2023 Revenue up 120%
- 2024 Revenue expected to treble (not including any new deals)
- Cost streamlining in place
Directors have skin in the game & bought most recently at 28p to 29.75p (prior to this at 80p)
- Staff share options exercisable at 25.75p
- Portrait+ Kit launched last week at San Antonio Breast Cancer Symposium.
Upcoming Catalysts
- Assay updates
- Molecular study results
- Major pharmaceutical deals (as per recent webinar)
- Due to the diverse service offering, the CEO has stated: “a single deal could be worth 100’s of millions”
- Pilot Study with Eisai
- “Breakthrough” study results
- 120p Berenberg broker forecast
- Pitching at Boston DDR summit and AJ Bell investor event in Feb.
Conclusion:
- Lack of commercial deals has been the main criticism. However, AGL’s working to simplify the service offering for easier commercialisation (new Portrait+ kit & molecular studies etc) Are AGL at a turning point?
Hi Rebs
Aside from Director buys well north of where the SP currently sits. It’s also worth noting staff options are only exercisable at 25.75p
Hi Compound,
It was a Proactive Investor live event in Mayfair and we are as yet waiting for the recording to be posted online. As soon as it is I will add the link.
Well Bantham.
I rarely have a crossed word with anyone and can usually see others' perspectives and be understanding. I had been as courteous and civil as I could be with you for the past month through your unwavering negativity (understandably you are negative as you've lost a lot of money here in the past), I have also tried to be civil whilst I overlooked your backhanded snide digs.
But sadly I think on the subject of AGL we will have to agree to disagree and both move on.
I will continue to post on this board anything of "actual relevance" to new and prospective investors, such as today's Motley Fool Buy Tip and the newly announced Feb 6th AJ Bell investor event and moving forward I will continue to be a contributor as and when I see fit. But sadly, whatever your agenda is, good or disingenuous, You have painted yourself into a corner lacking any credibility and I have lost all respect for you. Good luck with your future investments.
Bantham
May I refer you to a prior post of yours last month when the price was 11p:
“ Tomhuk - just got back from a nice dinner.
if Griffiths said that then IMO you should sell all your shares immediately.
I suggest if there’s one post you remember next year it’s this one.”
This was your response to me posting an email I had from CFO, Richard Griffiths, stating the reasons why they had brought the investor relations in the house and got rid of the manager.
If I’d have listened to you and the endless negative posts you insist on issuing I’d have missed out on a 200% rise to 35p. With my small slice at the near top I have added as we have dipped. Very happy with my holding here.
You have asked why I won’t admit things have played out as you’d expected. You said the presentation on November was more hype and wouldn’t amount to anything yet again. This is why I won’t:
Since the (above) “advice” AGL have:
- launched Portrait+ at the San Diego Symposium
- received great results from the Brain Tumour study by
- won a pilot study contract with a large pharma co
- had breakthrough results from the recently RNS’d study
- Berenberg research note of 120p
- pitched at last nights proactive event
- pitching soon at the Investor event hosted by AJ BELL
- DDR symposium in Boston at the end of the month.
The company have kept the momentum and marketing focused plan going since the November presentation. That is the reason why the price rose to 35p. The reason why it has retraced is due to prior placing worries (now resolved as per last night) and usual market mechanics. (Nothing ever goes up I n a straight line). Come on Bantham. You know all of this as you’ve been around long enough to see this for what it is. Let’s cut the BS.
I agree Rarhar, news must be in the offing on Bioview and yes Brett seems very target oriented
Bantham,
I’m not here for a quick 2 week hit n run trade. I’ve positioned my investment at 11p for a longterm hold.
You may be able to spook other investors with intraday fretting but I’m holding more more than my 50% profit (Approx) I currently have.
Has it occurred to you now might be the big turnaround. Or has the fact that you’ve continually lost money here in the past with poorly timed investments made you blinkered?
Yes indeed. Back to ANGLE
I must say, I am quite impressed with Brett. Throughout his career he’s managed sales organizations in both the US and Europe, has launched over 20 proprietary specialty diagnostic assays, executed 12 international market deals, executed 100+ US payer contracts, and over 200 business to business clinical testing service contracts.
Re Bioview I’ll look into dates etc… but yes well progressed
Clutching at straws Sangi?
You are quite obviously being purposefully misleading here Sangi.
You’re referring to slide 11 of the PDF below. It clearly states:
“HER2 targeting antibody-drug conjugate (ADC) being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as part of a US$ 2 billion deal”
This is clearly part a brief profile of Eisai for investors and doesn’t state ANGLE will be part of that.
What else would you like to mislead on from that paragraph?
That ANGLE have “Revenues >£4 billion >10,000 employees… Or ANGLE have “80 active oncology clinical trials >60,000 participants”
Very underhanded.
Here’s is the Slide PDF for all to see: https://angleplc.com/wp-content/uploads/2024/01/ANGLE-Presentation-Proactive-Investors-11jan24.pdf
Good to see AGL pitching at another investor event on Feb 6th in London hosted by AJ BELL and Shares magazine.
(Sangi will be a bit happier to have AJ BELL involved maybe as proactive weren’t to his taste)
“Great to see #AGL really on the front foot and market focussed. They’ll be pitching at the AJ Bell & @SHARESmag event in London on 6th February.
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-london-live-event-060224 “
https://x.com/redditdeluxe/status/1745746816463782202?s=46&t=IHEn1TE0c7FNFBktt6H8XQ
Not if you talk to yourself I suppose. Anyway, enough fun and games. Let’s get back to AGL. Well last night was quite positive overall…
Bentham, indeed it was funny. It’s interesting that Sangi et al can post as much as they want about the negative sides of AGL, but when I as an actual investor, increase my listing activity to match - I’m the one in a cult. Damned if you do etc